Ostoegenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by China Medical University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01323894
First received: March 24, 2011
Last updated: March 25, 2011
Last verified: March 2011
  Purpose

The first year purpose:

The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.


Condition
Primary Disease

Study Type: Observational
Official Title: Ostoegenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons Between Non-viral and Viral Administration in Tissue Engineered Bone Regeneration

Further study details as provided by China Medical University Hospital:

Estimated Enrollment: 3
Study Start Date: March 2011
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Detailed Description:

Our previous work is investigating the viral (Adv-BMP-2) administration for the development of a model to generate bones for possible use in clinical settings; the non-viral and viral administrations will be compared for best osteogenesis effects.

The first year purpose:

The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

  Eligibility

Ages Eligible for Study:   10 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients require surgery ner iliac or abdomen areas

Criteria

Inclusion Criteria:

  • age above 10 years old
  • The patients require surgery ner iliac or abdomen areas

Exclusion Criteria:

  • age below 10 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01323894

Locations
Taiwan
China Medical Universty Hospital Not yet recruiting
Taichung, Taiwan, 404
Contact: Chia-Ning Chang, M.D. Ph.D.    +886422052121 ext 2021    scnchang@gamil.com   
Sponsors and Collaborators
China Medical University Hospital
Investigators
Principal Investigator: Sopha Chia-Ning Chang, M.D. Ph.D. China Medical University Hospital
  More Information

No publications provided

Responsible Party: Sophia Chia-Ning Chang, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01323894     History of Changes
Other Study ID Numbers: DMR-99-IRB-122
Study First Received: March 24, 2011
Last Updated: March 25, 2011
Health Authority: Taiwan: Department of Health

ClinicalTrials.gov processed this record on August 26, 2014